Identifying tumor-specific antigens for vaccine and personalized medicine development is a slow and challenging process, often hindered by inefficient purification methods and incomplete data analysis. Current workflows struggle to comprehensively capture the diversity of immunogenic peptides presented by MHC complexes.

ImmuneSpec offers an immune peptidomics platform that leverages mass spectrometry to precisely identify immunogenic peptides, accelerating the discovery of tumor antigens. Their workflow incorporates high-yield purification methods, detailed mass spectrometry analysis, and robust data analysis to ensure complete coverage of immunogenic regions. By processing up to 96 samples simultaneously, ImmuneSpec achieves turnaround times up to two times faster than the industry standard, while also identifying up to 200% more peptides, even with less input material. The platform provides researchers with access to a comprehensive database of identified immunopeptides, including both self and non-self peptides.

High-outcome purification methods to maximize the yield of immunopeptides.

Detailed mass spectrometry analysis for precise identification of immunogenic regions at the amino acid level.

Robust data-analysis methodology for complete coverage of immunogenic regions and neoantigen discovery.

Ability to process up to 96 samples simultaneously, significantly reducing turnaround time.

Comprehensive database of identified immunopeptides (self and non-self peptides) for complete access.

Extensive quality control measures to ensure peak quality of project outcomes, including assessment of MHC complex solubilization and affinity purification efficiency.

Customizable analysis tailored to the specific needs of each project.

ImmuneSpec serves pharmaceutical companies seeking to speed up drug or vaccine development, life science and biotech companies ensuring product safety and efficacy, and CROs optimizing their journey to market.